COMPANY

Y-mAbs Therapeutics

ymabs.com ↗ · Mid-Atlantic

Keywords: antibody

Profile checked Oct 10, 2026

Timeline

Nov 4, 2024 Partnership Partnership / licensing: $2M (upfront, as published); deal value up to $31M (kept separate from upfront), announced Nov 4, 2024. Source: SEC filing. source ↗

Last 2 years.

Nov 4, 2024 Partnership / licensing: $2M (upfront, as published); deal value up to $31M (kept separate from upfront), announced Nov 4, 2024. Source: SEC filing. source ↗

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗